Get started
Kainos Group plc $LSE:KNOS Profits UP +14% to £77.2mLSE:KNOS Kainos Group plc is back in favour as adj pre-tax Profits UP +14% to £77.2m and reaching 14 Years of Consecutive Growth with Revenue hitting £382.4m! With the Workday Segment of the business growing to over £60m ARR and Cash topping +16% to £126m with NO Debt this is a business that has great long term growth as leading consultants in Workday Products and in the Generative AI space having invested more than £10m into training their 3,000 staff in this area. The COVID contracts have ended in their healthcare segment thus returning to more organic growth figures and the share price since 2021 reflected this.
LSE:KNOSLong
by jmo9191
Australian dollar eyes RBA minutesThe Australian dollar is unchanged at the time of writing, trading at 0.6692 in the European session. There are no economic releases out of the US or Australia today, which should translate into a quiet day for AUD/USD. The Aussie is coming off an excellent week, gaining 1.36% and hitting its highest level since January. In the month of May, AUD/USD has surged 3.4%. Tuesday will be busier, with the Reserve Bank of Australia releasing the minutes of the policy meeting earlier this month. At that meeting, there were no surprises as the RBA held the cash rate at 4.35% for a fourth straight time. Notably, the central bank discussed the possibility of a rate hike at the meeting, which was not the case at the March meeting. This was likely a response to first-quarter CPI, which was slightly higher than expected. CPI fell from 4.1% to 3.6%, missing the forecast of 3.5%. Service inflation remains sticky, which means that CPI is expected to continue to ease, but slowly. RBA policy makers are concerned that the path to the 2% inflation target will be bumpy and are hesitant to start lowering rates until they see evidence of sustainable price stability. The fact that a rate hike is on the table, albeit an unlikely scenario, indicates that the RBA remains cautious and somewhat hawkish, and a rate cut will have to wait until inflation shows a substantial decline. Australia will also release Westpac Consumer Sentiment on Tuesday. The index has declined two straight times and remains in negative territory as consumers remain surly about high interest rates and the high cost of living. The May release is expected to show an improvement, with a market estimate of a 0.9% gain. AUD/USD has support at 0.6681 and 0.6662 0.6714 and 0.6733 are the next resistance lines
LSE:CPI
by OANDA
BGEO Potential Breakdown (Bank of Georgia)BGEO has been in a nice uptrend for some time now but is it really the time to switch the flip now? What we see on a chart is a healthy correction and touching the trendline support but there is a big BUT. Amidst this current situation in Georgia, Tbilisi, people has been protesting the "Russian Law" which turned now into protesting the government itself. This could be start of the breakdown for LSE:BGEO in my opinion because the situation is only gonna get worse for Tbilisi if government keeps going against the people.
LSE:BGEOShort
by cryptoalienss
WATR Major Support Line, High Volume and RSI DivergenceFirstly, does WATR possess a high quality balance sheet and growth prospects on a fundamental level? YES!! The company has $23m cash and $21m of borrowings, with FCF increasing from $6m in 22 to an estimated $7.4m in 23 and $9m in 24, owing to a reduction in CAPEX. The only thing I don't like about the balance sheet is the high amount of intangible assets, but, these aren't set to increase and a high proportion is goodwill from acquisitions which will be amortised over time. Net margin remains high at 17.6% and is forecasted to be maintained at this level, with revenue growing from $71m in 22 to $90m in 25. In terms of technical analysis, WATR is hovering around a strong support uptrend on the weekly chart, against a positive divergence on the RSI. In 2021 the PE ratio sat at over 50, with this now down to sub-20, indicating that in the past investors were willing to pay 150% more than today's price. The orange lines dictate my price targets, however, I would be inclined to hold this as an investment for much longer.
LSE:WATRLong
by Doddle
Asc triangle moving up, with prior track record UK stockAsc triangle moving up, with prior track record UK stock height of triangle gives target, long term chart, confirmation given by UK FTSE also moving up, also European indices eg MIB moving up. Reliable steady stock Enter using limit orders on any pull backs to top of triangle Stop out if price re enters triangle Target trailing stop, take 85% at target, which becomes the new stop Look to build position using multiple limit orders for entry on market down days, add if the pattern pauses making smaller time period patterns Have fun!
LSE:COALong
by William_Playfair
CMC Markets found substantial support at 100GBXCMC markets hit a 3-year low of 100GBX after news of lower revenue expectations but found huge support at the level with an immediate jump of 16% in 2 trading days. Fundamentally, CMC is trading at around 1X revenue. Given that CMC is a global, established, and profitable company, with consistent growth in its customer base. I think that the 100 GBX price was a bottom where reversal is taking place. I expect the price to reach 220-270 GBX at around the next dividend payment at the end of November-beginning of December. Not financial advice. Do your own research.
LSE:CMCXLong
by notalireza
Breakout After multiple attempts at failing to break the blue resistance line price has closed strongly above this level today. The catalyst for this was the release of good results, check them out for yourself. In addition to this they have just got approval from their Spanish business for $5 billion. Ker-ching. They have also announced a £500 million share buyback program. Also of note is that two of the Directors have recently bought large chunks of stock. One bought £1.5 million worth the other over £0.5 million. Dividend yield %10. Winner, winner, chicken dinner !
LSE:VOD
by RIckAshby
3
BATS RSI Divergence, EMA targets and Support/Resistance Zones BATS is a company where its financial performance and robustness is not reflected by it's share price, mainly owing to investor sentiment towards the sector it sits within and the fear of ever changing regulation of its products. It is currently generating £8.5bn in free cash flow, more than enough to pay the annual dividend and please any accountant that the company's operations still produces high margin returns (although this is less obvious in the accounts due to the non-cash impairment of its assets). From a technical stand point the chart depicts a favourable time to enter into BATS, with price currently consolidating at a weekly demand zone. Furthermore, there has been a clear divergence between price and the RSI which has been growing over the last year. The longer these build, the higher probability of a sharp reversal. The crossing of the 20 and 50 EMA on the weekly chart has been a trustworthy indicators of changes in trend, with gap between these two MAs beginning to close. I am expecting price to move sharply towards the 100EMA and short term supply zone at £26.80, resulting in the crossing of the 20/50 EMA, which will propel the price towards the first significant supply zone at £32. From here there will be a final push before the end of the year with the price testing the 5 year high. All this will happen in an impulsive 5 wave pattern. If £22 is retested and fails to hold as support than the likelihood is for further declines. As an investor, stop losses should be set at £21.50 and profits should be taken at £36, representing a risk to reward of 7.4. Disclaimer: I entered into a position here on 7th May 2024
LSE:BATSLong
by Doddle
1
FTSE's Pharma Surge: A Closer Look at Leading StocksThe FTSE 100’s recent surge has been led by the pharmaceutical sector, marking a 13.7% increase in just the last month. Let’s delve into the standout performers that are leading the rally. AstraZeneca (AZN): +14.5% YTD AstraZeneca’s share price jumped higher following the release of a market-beating set of results… In the first quarter of 2024, AstraZeneca performed exceptionally well, surpassing analysts’ expectations with a 19% growth in revenue. This impressive growth was primarily driven by increased sales of its cancer drugs. The pharma giant reported a revenue of $12.7 billion, significantly outperforming consensus estimates, which had projected $11.9 billion. AstraZeneca also reiterated its guidance for the current year, expecting double-digit growth in both sales and earnings. On the price chart, the shares have now moved into a key area of resistance which represent the April 2023 all-time highs. Momentum traders will be watching closely for a break and close above this resistance as it could trigger AstraZeneca’s next trend leg higher. AZN Daily Candle Chart Past performance is not a reliable indicator of future results GlaxoSmithKline (GSK): +21.1% YTD Like AstraZeneca, GSK's share price has been buoyed by a strong set of first-quarter results… GSK’s recent trading statement showed improvements across various metrics, with revenue increasing by 10% to £7.4 billion and underlying operating profit rising by 27% to £2.4 billion, driven by robust growth in Vaccines and Speciality medicines. GSK's momentum from last year has continued into 2024, driven by strong financial performance and supported by excellence in research & development, which resulted in four major product approvals last year. Vaccines have emerged as a key growth driver, particularly with products like Shingrix and the recently approved RSV vaccine, Arexvy. The company's focus on HIV treatments and the shift towards long-acting innovation therapies has also contributed to growth in this segment. On the price chart, GSK is showing strong upwards momentum with the shares breaking above swing resistance at the start of this month. However, the July 2022 cluster of swing highs should provide some resistance in the coming weeks. GSK Daily Candle Chart Past performance is not a reliable indicator of future results Hikma Pharmaceuticals (HIK): +11.3% YTD Relative to AstraZeneca and GSK, Hikma has been a laggard with prices chopping sideways within a long-term wedge pattern (see chart below). That said, recent price action saw the shares print a large bullish reversal pattern following a market-beating trading statement… Hikma reported a 30% increase in profit, reaching $367 million last year, with revenue hitting $2.875 billion, up by 14% from the previous year. The core business saw operating profit up by 19%, mainly due to better profitability in both branded and generic segments. Generics experienced strong growth, with revenue up by 39% and core operating profit up by 86%. However, the company expects profits to be slightly lower in 2024 compared to last year. We are starting to see sector laggards like Hikma picking up momentum as the front runners, AZN and GSK move towards resistance. This indicates that the FTSE’s Pharma rally may be entering into the final phases. HIK Daily Candle Chart Past performance is not a reliable indicator of future results Disclaimer: This is for information and learning purposes only. The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance. Social media channels are not relevant for UK residents. Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.84% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
LSE:AZN
by Capitalcom
GLENCORE Analysis - Continuous, Just as the Markets !This is a Thread, so Follow for Technical Analysis performed with TrapZone Pro & UMVD Indicators. * Trend is Based on TrapZone Color * Bar Colors give us Momentum Green from strong Up Moves. Red Bars point to strong Down Moves. * Red UMVD = Selling Pressure & Green UMVD = Buying Pressure. Purple is for Divergence = Battle of Supply & Demand -------------------- 1-23-2024 Strong downtrend with RED TrapZone established for days now. Price retraces with GREEN UMVD but the effect is not the same as RED UMVD - Obviously. Price is retracing a bit again with GREEN UMVD coming in now.
LSE:GLEN
by SnowflakeTrader
3